| Name | Title | Contact Details |
|---|
Bigfoot Music Inc is a Arlington, WA-based company in the Business Services sector.
Quarterage At Westport Lp is a Kansas City, MO-based company in the Business Services sector.
Classic Kitchen & Bath is a Waterloo, IA-based company in the Business Services sector.
Labrador Technologies builds connections between companies and the data they invest in. Specializing in Data-Flow Management™, Labrador Technologies has the ability to retrieve and deliver data to the right place, at the right time. Whether delivering data to a Labrador application, a third-party application, an enterprise service bus, or a portal, Labrador gets the job done efficiently. Data-Flow Management™(DFM™) revolves around one central theme - the data you need, when you need it. Data-Flow Management™ comprises data-plumbing, data-adaptors, data integration, portal solutions, and `on-demand` data query and reporting applications - all of which contribute to, or actually create, the precise and timely flow of data. This responsive flow of data helps companies react quickly to changing conditions, resulting in an event-driven enterprise. Labrador Technologies` DFM™ software and services help software vendors, data vendors, and company developers deliver data to their target audiences by `plugging` users in and eliminating the need for expensive and ongoing manual intervention.
TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients own islet cell health.